Hints and tips:
...Actavis Holdco U.S., Inc.; Actavis Pharma, Inc.; Ascend Laboratories, LLC; Apotex Corp.; Dr....
...Such a transaction would continue the company’s three-year dealmaking spree, which has taken it from a run-of-the-mill generic drugmaker known as Watson Pharmaceuticals, with a market capitalisation of $8bn...
...In 2012 it was Watson Pharmaceuticals, a generic drugmaker with a market capitalisation of $8bn — a fraction of the $113bn it is worth today....
...In 2012, the group, then called Watson, was a run-of-the-mill producer of generic drugs with a market capitalisation of $8bn — a fraction of the $120bn it is worth today....
...The rise of Actavis has attracted little attention outside the pharma sector, partly because Mr Bisaro is shy of publicity....
...Actavis was a middling generics pharma company that has transformed itself through dealmaking....
...He left in 2007 to become chief executive at Watson, the generic drug company that would later acquire Swiss-based Actavis....
...Valeant and Actavis have been in the lead and the trend is spreading to Big Pharma, if Pfizer has its way....
...Private equity companies have been especially interested in contract research companies such as Medpace as a way to tap into the rich seam of research and development spending by big pharma companies....
...In the first, Valeant bought Bausch & Lomb for $8.7bn after losing the race for Actavis, Elan and Royalty Pharma continued to squabble over valuations and AstraZeneca made a small bolt-on purchase....
...The market is delighted by Watson Pharmaceuticals’ €4.5bn acquisition of Switzerland’s Actavis....
...Nestlé paid a hefty $12bn for Pfizer’s infant nutrition business to gain emerging market share, and Watson agreed a €4.5bn takeover of Actavis to create one of the world’s largest generic drugs group....
...“There are a number of actions coming,” says Paul Bisaro, head of Watson, the US generic medicines company. “The probes are causing a lot of people to sit up and take notice.”...
International Edition